Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Related to this article
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Zabilugene Almadenorepvec Plus Chemo Shows Survival Gains in Metastatic PDAC
2
Telehealth May Offer a Path to More Equitable Myeloma Transplant Access
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
In CML, Future Directions Include TKI Sequencing Strategies and Mutational Profiles
5